Diagnostic criteria for apathy in clinical practice

Mulin, Emmanuel; Leone, Elsa; Dujardin, Kathy; Delliaux, Marie; Leentjens, Albert F.G.; Nobili, Flavio; Dessi, Barbara; Tible, Olivier; Agüera-Ortíz, Luis; Osorio, Ricardo S.; Yessavage, J.; Dachevsky, D.; Verhey, Frans R.J.; Cruz-Jentoft, Alfonso J.; Blanc, O.; Llorca, P.M.; Robert, Philippe

doi:10.1002/gps.2508

Cited by 194 publications

(139 citation statements)

References 35 publications

Supporting

Mentioning

125

Contrasting

Unclassified

Order By: Relevance

“…However, previous research has shown some evidence that apathy is multidimensional e.g.. [1,12], with the proposed diagnostic criteria of apathy recognizing the syndromatic nature of apathy [13,14] but without a thorough measurement of specific subtypes [15]. This has been observed in dementia using traditional one-dimensional assessment tools such as the Neuropsychiatric Inventory (NPI) [16].…”

Section: Introductionmentioning

confidence: 99%

A Novel Assessment and Profiling of Multidimensional Apathy in Alzheimer’s Disease

Radaković

Starr

Abrahams

2017

JAD

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

A Novel Assessment and Profiling of Multidimensional Apathy in Alzheimer’s Disease

Radaković

Starr

Abrahams

2017

JAD

View full text Add to dashboard Cite

show abstract

“…Benoit et al (2011) suggested that imagining and anticipating an episode of pleasure (e.g., the receipt of a reward) with high emotional intensity and many phenomenological details might constitute an intrinsic source of motivation. It could be then hypothesized that the inability to project oneself into the future, and especially into future episodes of pleasure, may contribute to the existence of apathetic manifestations (e.g., loss of initiative or interest; see Mulin et al, 2011 for the diagnostic criteria of apathy) in schizophrenia. In this regard, it is interesting to consider the concept of anhedonia (characterized by a loss of pleasure) in parallel to apathy.…”

Section: Introductionmentioning

confidence: 99%

“…Moreover, several studies on anhedonia in schizophrenia showed that patients have anticipatory pleasure deficits but normal levels of positive feelings (i.e., consummatory pleasure) when processing emotional stimuli (see Cohen and Minor, 2010, for a review). This may suggest that patients do not manifest disinterest (a dimension of apathy; see Mulin et al, 2011) in current activities. According to Heerey et al (2011), anticipatory pleasure deficits in schizophrenia patients could be due to degraded representations of future pleasurable events (e.g., rewards), which might account for their lower likelihood of pursuing pleasurable activities and thus their reduced GDB.…”

Section: Introductionmentioning

confidence: 99%

Impaired ability to imagine future pleasant events is associated with apathy in schizophrenia

Raffard

Esposito

Boulenger

et al. 2013

Psychiatry Research

View full text Add to dashboard Cite

a b s t r a c tRecent research has established that schizophrenia patients have difficulties envisioning the future. Although mental simulations have a clear adaptive value, little is known about the function of simulating future episodes, particularly emotional events. The aim of this study was to explore the relationships between apathy and future projection in schizophrenia. Twenty-five schizophrenia patients and 25 healthy controls were asked to imagine pleasant and unpleasant episodes that might happen to them in the future. Verbal descriptions were scored for specificity, and participants also completed the Memory Characteristics Questionnaire, which assesses phenomenal characteristics of imagined future events. Apathy was assessed with the Lille Apathy Rating Scale and the apathetic/social withdrawal item of the Positive and Negative Syndrome Scale. Results showed that schizophrenia patients' pleasant and unpleasant imagined future events were less specific and contained fewer phenomenal characteristics (e.g., amount of sensory details) than those of controls. In the schizophrenia group, difficulties imagining future pleasant events, and particularly poor self-referential information for future pleasant events, were specifically associated with apathy, even after controlling for working memory. These results suggest that episodic future thinking impairments, especially for future events of pleasure, may partly underlie the motivational deficits characteristic of schizophrenia.

show abstract

“…A significantly increased apathy score on the NPI has been reported for individuals in a clinical practice setting who fulfilled the proposed diagnostic criteria for apathy (20). …”

Section: Issues In Designing a Trial To Test Treatments For Apathymentioning

confidence: 99%

Designing a Trial to Evaluate Potential Treatments for Apathy in Dementia: The Apathy in Dementia Methylphenidate Trial (ADMET)

Drye

Scherer

Lanctôt

et al. 2013

The American Journal of Geriatric Psychiatry

View full text Add to dashboard Cite

Background Research on efficacious treatments for apathy in Alzheimer’s disease has been hindered by a lack of consensus diagnosis, difficulties in measurement, and studies with small sample sizes. Methods In designing the Apathy in Dementia Methylphenidate Trial (ADMET), a trial to evaluate the efficacy and safety of methylphenidate for the treatment of apathy in Alzheimer’s disease, we encountered the following issues: defining and measuring apathy, distinguishing apathy and depression, determining an appropriate test treatment, selecting relevant secondary outcomes, recruiting participants, and deciding on a suitable method for treatment unmasking. ADMET is a 6-week randomized, double-masked, placebo-controlled multicenter clinical trial with two parallel treatment groups assigned in a 1:1 ratio with randomization stratified by clinical center. The recruitment goal is 60 randomized participants over 2 years. The primary outcomes are change in apathy severity as measured by the Apathy Evaluation Scale and the Alzheimer Disease Cooperative Study-Clinical Global Impression of Change. Conclusion The design decisions made for ADMET are important elements to be considered in trials assessing the safety and efficacy of medications for clinically significant apathy in Alzheimer’s disease.

show abstract

Diagnostic criteria for apathy in clinical practice

Abstract: This study is the first one to test the diagnostic criteria for apathy in clinical practice. Results make the diagnostic criteria useful for clinical practice and research.

Cited by 194 publications

References 35 publications

A Novel Assessment and Profiling of Multidimensional Apathy in Alzheimer’s Disease

A Novel Assessment and Profiling of Multidimensional Apathy in Alzheimer’s Disease

Impaired ability to imagine future pleasant events is associated with apathy in schizophrenia

Designing a Trial to Evaluate Potential Treatments for Apathy in Dementia: The Apathy in Dementia Methylphenidate Trial (ADMET)

Contact Info

Product

Resources

About